New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;FB;PMFG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
October 24, 2014
16:02 EDTBMY, FBOptions Update; October 24, 2014
Subscribe for More Information
11:19 EDTFBFacebook October weekly volatility elevated into Q3 and revenue outlook
Subscribe for More Information
11:15 EDTBMYBristol-Myers says has capacity for large deal
Subscribe for More Information
10:42 EDTBMYBristol-Myers sees coming in closer to high end of FY14 EPS guidance
Subscribe for More Information
10:10 EDTBMYBristol-Myers to host conference call
Conference call to review data presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology (CMSTO) will be held on October 31 at 2:30 pm. Webcast Link
07:35 EDTBMYBristol-Myers reports Q3 Eliquis revenue $216M
Reports Q3 Baraclude revenue $325M, Sprycel revenue $385M, Yervoy revenue $350M. Reports Q3 Abilify revenue $449M, Orencia revenue $444M.
07:33 EDTBMYBristol-Myers confirms FY14 adjusted EPS view $1.70-$1.80, consensus $1.78
Cuts FY14 GAAP EPS view to $1.15-$1.25 from $1.50-$1.60. Both GAAP and non-GAAP guidance assume current exchange rates and that the R&D tax credit will be extended by Congress in 2014. Sees FY14 worldwide revenue $15.2B-$15.8B, consensus $15.58B. Also sees: Full-year gross margin as a percentage of revenues between 75% and 76%. Advertising and promotion expense decreasing in the mid-teen-digit range. Marketing, sales and administrative expenses decreasing in the mid-single-digit range. Research and development expenses growing in the mid-single-digit range. An effective tax rate of 19% - 20%.
07:31 EDTBMYBristol-Myers reports Q3 adjusted EPS 45c, consensus 42c
Subscribe for More Information
October 23, 2014
16:00 EDTFBOptions Update; October 23, 2014
iPath S&P 500 VIX Short-Term Futures down 2.04 to 33.48. Option volume leaders: AAPL TSLA TWTR F AMZN FB NFLX PBR P according to Track Data.
15:39 EDTBMYNotable companies reporting before tomorrow's open
Subscribe for More Information
13:27 EDTFBFacebook launches Rooms app
Facebook earlier today announced that it would launch an app that will enable users to create chat rooms based on different topics. Reference Link
11:38 EDTFBStocks with call strike movement; FB VALE
Facebook (FB) March 90 call option implied volatility decreased 3% to 35, Vale (VALE) March 12 call option implied volatility decreased 3% to 33 according to IVolatility.
October 22, 2014
16:00 EDTFBOptions Update; October 23, 2014
Subscribe for More Information
13:42 EDTFBFacebook October weekly volatility elevated into Q3 and revenue outlook
Subscribe for More Information
09:38 EDTFBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR AMZN C TWTR YHOO BAC GILD FB THRX DOW CAR
October 21, 2014
16:00 EDTFBOptions Update; October 21, 2014
Subscribe for More Information
07:15 EDTBMYFDA to hold workshop on breast cancer drug development
Subscribe for More Information
06:09 EDTFBTwitter initiated with a Neutral at Citigroup
Subscribe for More Information
06:04 EDTFBFacebook sues laywers who represented Ceglia, Re/code reports
Subscribe for More Information
October 20, 2014
12:03 EDTFBKing Digital launches Candy Crush Soda Saga worldwide on Facebook
Earlier today, King Digital Entertainment (KING) announced that Candy Crush Soda Saga, the sister title to hit game Candy Crush Saga, has launched worldwide on Facebook (FB). Candy Crush Soda Saga is the next iteration in the Candy Crush franchise, set in the world of the Candy Kingdom. Fans of the original hit can now switch and match their way through new dimensions of gameplay with exciting new graphics and features including game modes, candy combinations, gameplay mechanics and more. Candy Crush Soda Saga is set to launch on mobile in the coming weeks.
11:42 EDTFBStocks with call strike movement; FB DAL
Subscribe for More Information
07:32 EDTPMFGPMFG announces environmental systems awards totaling $6.5M
Subscribe for More Information
07:19 EDTBMYIBC Life Sciences to hold a conference
Subscribe for More Information
October 17, 2014
16:01 EDTFBOptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
October 16, 2014
10:01 EDTBMYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:39 EDTFBActive equity options trading on open
Subscribe for More Information
08:42 EDTBMYBristol-Myers upgraded at BMO Capital
Subscribe for More Information
06:16 EDTBMYBristol-Myers upgraded to Outperform from Market Perform at BMO Capital
October 15, 2014
12:02 EDTFBStocks with call strike movement; FB WMB
Facebook (FB) March 80 call option implied volatility increased 4% to 80, Williams (WMB) February 57.5 call option implied volatility increased 5% to 41 according to IVolatility.
09:57 EDTBMYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:20 EDTFBFacebook likely to beat Q3 expectations, says Oppenheimer
Subscribe for More Information
07:11 EDTFBFacebook should be bought into Q3 results, says Deutsche Bank
Subscribe for More Information
06:43 EDTFBFacebook, Samsung could collaborate to develop mobile content, Korea Times says
Subscribe for More Information
October 14, 2014
11:23 EDTBMYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
13:10 EDTFBGoogle's Schmidt says Amazon is company's biggest search rival, FT reports
Eric Schmidt, the executive chairman of Google (GOOG), says Amazon (AMZN) is his company's biggest rival in search, not Bing (MSFT) or Yahoo (YHOO), the Financial Times reports. Schmidt also argued in Berlin that Google should not be regulated "as if it were the gatekeeper of the internet," given the influence of Amazon and Facebook (FB). Reference Link
09:39 EDTFBActive equity options trading on open
Subscribe for More Information
08:05 EDTBMYBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:13 EDTBMYBioFlorida to hold a conference
Subscribe for More Information
05:15 EDTFBFacebook, Ericsson, XL Axiata innovate to improve Indonesia network performance
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use